[Clinical evaluation of glipizide. Results of a multicentric study in Spain].
In this study, with the evaluation of 621 diabetics under treatment, it is shown that glipizide is a potent oral sulfonilurea which controlled satisfactorily the blood sugar levels in 83,5% of diabetics without previous treatment, 67% of the cases with positive response to previous anti-diabetic therapy and 51,3% of the patients that had not responded to previous treatments. The most frecuently used dosage was 5 mg daily, with a minimum of 2,5 mg and a maximum of 30 mg. Tolerance and safety observed was excellent.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004341:Drug Evaluation; D005913:Glipizide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013030:Spain; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors
D013453:Sulfonylurea Compounds; D005913:Glipizide
Evaluación clínica de glipicida. Resultados de un estudio multicéntrico en Espanña